Molina Healthcare, Inc.: Form 10-Q for the period ended Jun 30, 2023
Filed with the SEC on Jul 27, 2023 and accepted by EDGAR at Jul 27, 2023, 09:43 ET.
Sections
No standard item headings were found in this filing’s main document, so no sections were extracted. Read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2023-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2023-04-01 to 2023-06-30 | $8.33bn | us-gaap:Revenues |
| Revenue | 6 months2023-01-01 to 2023-06-30 | $16.48bn | us-gaap:Revenues |
| Cost of revenue | 3 months2023-04-01 to 2023-06-30 | $7.04bn | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 6 months2023-01-01 to 2023-06-30 | $13.91bn | us-gaap:CostOfGoodsAndServicesSold |
| Operating income | 3 months2023-04-01 to 2023-06-30 | $443.0m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2023-01-01 to 2023-06-30 | $898.0m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2023-04-01 to 2023-06-30 | $27.0m | us-gaap:InterestExpense |
| Interest expense | 6 months2023-01-01 to 2023-06-30 | $55.0m | us-gaap:InterestExpense |
| Income tax | 3 months2023-04-01 to 2023-06-30 | $107.0m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2023-01-01 to 2023-06-30 | $213.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2023-04-01 to 2023-06-30 | $309.0m | us-gaap:NetIncomeLoss |
| Net income | 6 months2023-01-01 to 2023-06-30 | $630.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2023-04-01 to 2023-06-30 | $5.35 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2023-01-01 to 2023-06-30 | $10.87 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2023-04-01 to 2023-06-30 | $5.37 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2023-01-01 to 2023-06-30 | $10.95 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2023-04-01 to 2023-06-30 | 57,900,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2023-01-01 to 2023-06-30 | 58,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2023-01-01 to 2023-06-30 | $1.40bn | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2023-01-01 to 2023-06-30 | $63.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 6 months2023-01-01 to 2023-06-30 | $0 | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2023-06-30 | $4.91bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2023-06-30 | $11.44bn | us-gaap:AssetsCurrent |
| Total assets | At period end2023-06-30 | $13.66bn | us-gaap:Assets |
| Current liabilities | At period end2023-06-30 | $7.54bn | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2023-06-30 | $10.04bn | us-gaap:Liabilities |
| Long-term debt | At period end2023-06-30 | $2.18bn | us-gaap:LongTermDebtNoncurrent |
| Shareholders' equity | At period end2023-06-30 | $3.62bn | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001179929-23-000098. Last ingested by Listed: Nov 11, 2026, 00:18 ET. Listed shows no prices and gives no investment advice.